Olema Pharmaceuticals, Inc.
OLMA
Positions held
Your positionsOLMA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $684.23M | Enterprise value | $226.82M | Trailing P/E | — | Forward P/E | -2.97 |
| PEG | — | Price / book | 1.59 | Beta | 2.01 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -52.7% | ROA | -31.8% | Debt / equity | 0.01 |
| Current ratio | 8.86 | Free cash flow | -$89.06M | Analyst recommendation | none | Mean target | $36.50 |
| 52w high | $36.26 | 52w low | $6.65 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$63.2M | -$53.1M | -$46.1M | -$42.2M | -$43.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$67.2M | -$58.0M | -$50.1M | -$45.9M | -$47.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$162M | -$129M | -$96.7M | -$105M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$179M | -$142M | -$105M | -$107M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-14 · Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
2026-09-14 · Top Premarket Decliners
2026-09-14 · Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
2026-09-02 · Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-31 · Olema Oncology to Participate in Upcoming Investor Conferences
2026-08-13 · Olema Pharmaceuticals Names Jason O'Byrne CFO
2026-08-13 · Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
2026-08-10 · Olema Pharmaceuticals Q2 Loss Widens
2026-08-10 · Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
2026-08-04 · Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns